Ghent University Academic Bibliography

Advanced

Combining iodine-131 lipiodol therapy with low-dose cisplatin as a radiosensitiser: preliminary results in hepatocellular carcinoma

B Brans, K Van Laere, F Gemmel, Luc Defreyne UGent, Peter Vanlangenhove, Roberto Troisi UGent, Hans Van Vlierberghe UGent, Isabelle Colle UGent, Bernard de Hemptinne and Rudi Dierckx UGent (2002) EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 29(7). p.928-932
abstract
A prospective pilot trial was performed in 20 patients randomised to receive either I-131-Lipiodol therapy alone (n=10) or I-131-Lipiodol combined with a short low-dose cisplatin infusion (n=10), the aim being to evaluate the possible positive influence of a radiosensitiser on toxicity and tumour response. An activity of 1,354-2,128 MBq (mean 1,824 MBq) [36.6-57.5 mCi (mean 49.3 mCi)] I-131-labelled Lipiodol was administered by selective instillation in the hepatic artery. Cisplatin was given in a dose of 30 mg/m(2) at day -1 and day +6 (day 0: I-131-Lipiodol). The primary endpoint of this trial was toxicity of therapy; points of secondary interest were tumour response and survival at 6 months. With the use of cisplatin we found a higher percentage of stable or diminished tumour size (90%, vs 40% without). A benefit in group survival at 6 months was not evident. Low-grade stomatitis in one patient and minor changes in peripheral blood count were probably directly related to cisplatin, but its administration is unlikely to be associated with an excess of serious side-effects. The use of low-dose cisplatin infusion as a radiosensitising agent in I-131-Lipiodol therapy for hepatocellular carcinoma seems safe and may be beneficial for tumour control. Larger patient groups are necessary for confirmation and to establish the future role of I-131-Lipiodol in hepatocellular carcinoma.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
cisplatin, hepatocellular carcinoma, radiosensitiser, INTERNAL RADIATION-THERAPY, CHEMOTHERAPY, RADIOTHERAPY, iodine-131, lipiodol, intra-arterial liver therapy
journal title
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Eur. J. Nucl. Med. Mol. Imaging
volume
29
issue
7
pages
928 - 932
Web of Science type
Article
Web of Science id
000177001600013
JCR category
RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
JCR impact factor
3.568 (2002)
JCR rank
6/81 (2002)
JCR quartile
1 (2002)
ISSN
1619-7070
DOI
10.1007/s00259-002-0791-8
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
316026
handle
http://hdl.handle.net/1854/LU-316026
date created
2005-06-16 14:26:00
date last changed
2016-12-19 15:42:26
@article{316026,
  abstract     = {A prospective pilot trial was performed in 20 patients randomised to receive either I-131-Lipiodol therapy alone (n=10) or I-131-Lipiodol combined with a short low-dose cisplatin infusion (n=10), the aim being to evaluate the possible positive influence of a radiosensitiser on toxicity and tumour response. An activity of 1,354-2,128 MBq (mean 1,824 MBq) [36.6-57.5 mCi (mean 49.3 mCi)] I-131-labelled Lipiodol was administered by selective instillation in the hepatic artery. Cisplatin was given in a dose of 30 mg/m(2) at day -1 and day +6 (day 0: I-131-Lipiodol). The primary endpoint of this trial was toxicity of therapy; points of secondary interest were tumour response and survival at 6 months. With the use of cisplatin we found a higher percentage of stable or diminished tumour size (90\%, vs 40\% without). A benefit in group survival at 6 months was not evident. Low-grade stomatitis in one patient and minor changes in peripheral blood count were probably directly related to cisplatin, but its administration is unlikely to be associated with an excess of serious side-effects. The use of low-dose cisplatin infusion as a radiosensitising agent in I-131-Lipiodol therapy for hepatocellular carcinoma seems safe and may be beneficial for tumour control. Larger patient groups are necessary for confirmation and to establish the future role of I-131-Lipiodol in hepatocellular carcinoma.},
  author       = {Brans, B and Van Laere, K and Gemmel, F and Defreyne, Luc and Vanlangenhove, Peter and Troisi, Roberto and Van Vlierberghe, Hans and Colle, Isabelle and de Hemptinne, Bernard and Dierckx, Rudi},
  issn         = {1619-7070},
  journal      = {EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING},
  keyword      = {cisplatin,hepatocellular carcinoma,radiosensitiser,INTERNAL RADIATION-THERAPY,CHEMOTHERAPY,RADIOTHERAPY,iodine-131,lipiodol,intra-arterial liver therapy},
  language     = {eng},
  number       = {7},
  pages        = {928--932},
  title        = {Combining iodine-131 lipiodol therapy with low-dose cisplatin as a radiosensitiser: preliminary results in hepatocellular carcinoma},
  url          = {http://dx.doi.org/10.1007/s00259-002-0791-8},
  volume       = {29},
  year         = {2002},
}

Chicago
Brans, B, K Van Laere, F Gemmel, Luc Defreyne, PETER VANLANGENHOVE, Roberto Troisi, Hans Van Vlierberghe, Isabelle Colle, Bernard de Hemptinne, and Rudi Dierckx. 2002. “Combining Iodine-131 Lipiodol Therapy with Low-dose Cisplatin as a Radiosensitiser: Preliminary Results in Hepatocellular Carcinoma.” European Journal of Nuclear Medicine and Molecular Imaging 29 (7): 928–932.
APA
Brans, B, Van Laere, K., Gemmel, F., Defreyne, L., VANLANGENHOVE, P., Troisi, R., Van Vlierberghe, H., et al. (2002). Combining iodine-131 lipiodol therapy with low-dose cisplatin as a radiosensitiser: preliminary results in hepatocellular carcinoma. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 29(7), 928–932.
Vancouver
1.
Brans B, Van Laere K, Gemmel F, Defreyne L, VANLANGENHOVE P, Troisi R, et al. Combining iodine-131 lipiodol therapy with low-dose cisplatin as a radiosensitiser: preliminary results in hepatocellular carcinoma. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2002;29(7):928–32.
MLA
Brans, B, K Van Laere, F Gemmel, et al. “Combining Iodine-131 Lipiodol Therapy with Low-dose Cisplatin as a Radiosensitiser: Preliminary Results in Hepatocellular Carcinoma.” EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 29.7 (2002): 928–932. Print.